Novartis receives third FDA approval for oral Fabhalta® (iptacopan) – the first and only treatment approved in C3 glomerulopathy (C3G) Fabhalta is the only oral alternative complement pathway ...

One of them, a SNO protein called complement component 3 (C3) that plays a role in the autoimmune system, was found in considerably greater quantities in the brains of female Alzheimer’s patients than ...

Discover how Apellis Pharmaceuticals, Inc. surpasses Q4 expectations with impressive revenue growth and cost reductions.

DelveInsight's "EMPAVELI Market Size, Forecast, and Market Insight Report" highlights the details around EMPAVELI, a ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) released topline results from Part 2 of a Phase 1/2 study of ARO-C3, the ...

By silencing C3, investigational ARO-C3 has the potential to treat complement-mediated renal ... thereby affecting the production of a specific protein. Arrowhead’s RNAi-based therapeutics ...

Researchers at Lund University have studied a protein called C3, which plays a central role in the body's immune system. The protein is secreted from cells and is found in large quantities in the ...

The complement system is a central component of innate immunity, consisting of a large family of plasma and membrane bound proteins that are critical for protection against bacterial infection and ...

Novartis Media Relations E-mail: [email protected] Novartis Investor Relations Central investor relations line: +41 61 ...